MAYO CLINIC LABORATORIES

TEST OBSOLETE

Notification Date: Nov 3, 2026
Effective Date: Dec 3, 2026

Carrier Screen, Focused Panel, Varies

Test ID: CSFP

Explanation:
On the effective date, test ID CSFP will be obsoleted. Recommended alternative testing based on clinical indication is listed below. For further specimen and testing details, refer to the Mayo Clinic Laboratories Test Catalog.

Recommended Alternative Tests:

Test ID	Test Name	Useful For
CFMP	Cystic Fibrosis, *CFTR* Gene, Variant Panel, Varies	Confirmation of a clinical diagnosis of **cystic fibrosis** Reproductive risk refinement via carrier screening for individuals in the general population or for individuals with a family history when familial variants are not available Identification of patients who may respond to cystic fibrosis transmembrane conductance regulator (*CFTR*) potentiator therapy
CFTRN	Cystic Fibrosis Transmembrane Conductance Regulator, *CFTR*, Full Gene Analysis, Varies	Carrier screening for **cystic fibrosis** Follow-up testing to identify variants in individuals with a clinical diagnosis of cystic fibrosis (CF) Identifying genetic variants in individuals with atypical presentations of CF (eg, congenital bilateral absence of the vas deferens or pancreatitis) Identifying genetic variants in individuals where detection rates by targeted variant analysis are low or unknown for their ancestral background Identifying patients who may respond to cystic fibrosis transmembrane conductance regulator (*CFTR*) potentiator therapy

© Mayo Foundation for Medical Education and Research. All rights reserved.

SMNCS	Spinal Muscular Atrophy Carrier Screening, Deletion/Duplication Analysis, Varies	General population carrier screening for **spinal muscular atrophy** (SMA) Carrier screening for reproductive partners of known SMA carriers Carrier screening for parents of a child with a known deletion of the survival motor neuron 1 gene (*SMN1*) or other family history of SMA
AGDD	Alpha Globin Cluster Locus Deletion/Duplication, Varies	Diagnosis of **alpha-thalassemia** Carrier screening for individuals from high-risk populations for alpha-thalassemia
WBSEQ	Beta Globin Gene Sequencing, Varies	Diagnosis of **beta thalassemia** intermedia or major Identification of a specific beta thalassemia sequence variant (ie, unusually severe beta thalassemia trait) Evaluation of an abnormal hemoglobin electrophoresis identifying a rare beta-globin variant Evaluation of chronic **hemolytic anemia** of unknown etiology Evaluation of **hereditary erythrocytosis** with left-shifted p50 oxygen dissociation results Preconception screening when there is a concern for a **beta-hemoglobin disorder** based on family history
FXS	Fragile X Syndrome, Molecular Analysis, Varies	Confirming a diagnosis of **fragile X syndrome**, f**ragile X tremor/ataxia syndrome**, or **premature ovarian insufficiency** caused by expansions in the *FMR1* gene Determining carrier status for individuals with a family history of fragile X syndrome or **X-linked intellectual disability** Prenatal diagnosis of fragile X syndrome when there is a documented *FMR1* expansion in the family

Questions

Contact Sarah Wittwer, Laboratory Resource Coordinator at 800-533-1710.

© Mayo Foundation for Medical Education and Research. All rights reserved.